Searched for
SPIL
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...- Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trialsSun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for ...
- Nvidia plans to manufacture AI chips in the US for the first timeNvidia's announcement comes as the Trump administration has said that tariff exemptions on electronics like smartphones and laptops are onl...
- Shakti Pumps Q2 Results: PAT soars to Rs 101 croreDuring the second quarter, the company's revenue from operations also rose four-fold to Rs 634.6 crore, from Rs 152.8 crore a year ago.
- Sun Pharma settles fund diversion case with SebiThe move could be a booster for Sun Pharma shares as corporate governance issues have weighed investor sentiment for the past two years.
- Sun Pharma, officials including Dilip Shanghvi settle case of alleged mkt norms violation with SebiThe firm's whole-time directors - Sudhir V Valia and Sailesh T Desai - paid Rs 37.41 lakh each, and Kalyanasundaram Subramanian had to remi...
- Suzlon December quarter loss narrows to Rs 118 croreConsolidated net loss had stood at Rs 742.91 crore in the quarter ended December 31, 2019, the company said.
- Buy Sun Pharmaceutical Industries, target Rs 581: Nirmal Bang Institutional EquitiesBuy Sun Pharmaceutical Industries at a price target of Rs 581.
- SPARC, Sun Pharma drop on USFDA revocation of approvalShares of SPARC closed 2.62 per cent lower at Rs 375.80 after hitting the day's low of Rs 368.50 on the exchange. Parent Sum Pharma ended 3...
- Forex gains drive Maruti Q1 net up 49 per centNet turnover from operations during the quarter fell 5% to Rs 9,995 crore compared to Rs 10,529 crore in the same period a year ago.
- Analysts’ view on how to trade Maruti Suzuki ahead of Q1 resultsMaruti is likely to report a net profit of Rs 660 cr, up 55.7%, as compared to Rs 423.8 cr in the corresponding quarter last fiscal.
- Maruti Suzuki Q1 PAT seen 55% up at Rs 660 croreSales for April-June quarter are seen at Rs 10,025 crore, down 7 per cent, as compared to Rs 10,778.1 crore in year-ago period.
- Brokerages increase Maruti Suzuki’s target price after strong Q4 resultsKotak said Maruti can outperform the industry in FY14 on account of expected pick-up in petrol car demand, additional diesel engine capacit...
- Maruti Suzuki Q4 net profit up 80% at Rs 1,148 crore, smashes forecastsMaruti posted better than expected profit, led by strong volumes of high margin diesel cars like Swift, Swift Dzire and Ertiga
- Maruti Suzuki shares surge over 5% on robust earningsShares MSI today surged over 5 per cent, after the company reported 79.4 per cent jump in standalone net profit for the quarter ended March...
- Suzuki Motor's stake in Maruti Suzuki goes up to 56.21 pcSuzuki Motor Corp's stake in subsidiary Maruti Suzuki has gone up to 56.21% after merger of Suzuki Powertrain into India's largest car make...
- Citigroup maintains 'buy' rating on Maruti SuzukiCitigroup has maintained a 'Buy' rating on Maruti Suzuki with a price target of Rs 1,654.
- CCI approves Sasan Power Infra merger with Reliance PowerCompetition watchdog CCI has approved the merger of Sasan Power Infrastructure with its parent firm Reliance Power.
- Buy call on Sun Pharma by Religare & MotilalReligare Research has maintained ‘buy’ on Sun Pharmaceutical Industries for a revised target of Rs 1,664 (Rs 1,347 previously), based on 18...
- Sun Pharma's demerged entity lists at Rs 87.15 on BSESun Pharma Advanced Research Company (SPARC), a demerged unit of Sun Pharma, today got listed at Rs 87.15 on the Bombay Stock Exchange (BSE...
Load More
